0000000000718460

AUTHOR

Alexandre Guilhem

showing 2 related works from this author

Correction to: The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome

2021

Although immune modulation is a promising therapeutic avenue in coronavirus disease 2019 (COVID-19), the most relevant targets remain to be found. COVID-19 has peculiar characteristics and outcomes, suggesting a unique immunopathogenesis.Thirty-six immunocompetent non-COVID-19 and 27 COVID-19 patients with severe pneumonia were prospectively enrolled in a single center, most requiring intensive care. Clinical and biological characteristics (including T cell phenotype and function and plasma concentrations of 30 cytokines) and outcomes were compared.At similar baseline respiratory severity, COVID-19 patients required mechanical ventilation for significantly longer than non-COVID-19 patients …

Male2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Critical CareSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralMEDLINElcsh:MedicineLymphocyte ActivationSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular BiologyImmunophenotypingmedicineHumansAgedAged 80 and overInnate immune systembusiness.industrySARS-CoV-2lcsh:RCorrectionCOVID-19General MedicineMiddle Agedmedicine.diseasePrognosisRespiration ArtificialImmunity InnatePneumoniaImmunologyFemaleFrancebusinessJournal of Translational Medicine
researchProduct

Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients.

2017

Dapsone is recommended as a second line therapy in immune thrombocytopenia (ITP), but is underused because of its potential side effects. The medical charts of 42 ITP patients treated with dapsone (100 mg/day) were retrospectively reviewed in order to assess its efficacy and safety in daily clinical practice. The overall response rate was 54.8% (n = 22, with a complete response in 38.1%) with a median time to response of 29 days (24-41 days). Patients with complete response had shorter disease duration whereas no difference was observed between responders and non-responders regarding age, sex or previous treatments received. Importantly, after dapsone withdrawal, a sustained response was ob…

Adultmedicine.medical_specialtymedicine.medical_treatmentSplenectomylcsh:Medicine030204 cardiovascular system & hematologyDapsone03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansAdverse effectlcsh:ScienceRetrospective StudiesSecond-line therapyPurpura Thrombocytopenic IdiopathicMultidisciplinarybusiness.industrylcsh:RRetrospective cohort studyImmune thrombocytopeniaSurgerySustained responseCohortlcsh:QbusinessDapsone030215 immunologymedicine.drugResearch ArticlePloS one
researchProduct